Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics

Abiraterone acetate (AA) has been proven effective for metastatic castration-resistant prostate cancer (mCRPC), and it has been proposed that adaptive AA may reduce toxicity and prolong time to progression, when compared to continuous AA. We developed a simple quantitative model of prostate-specific...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neoplasia
Main Authors: Brady-Nicholls, Renee, Zhang, Jingsong, Zhang, Tian, Wang, Andrew Z., Butler, Robert, Gatenby, Robert A., Enderling, Heiko
Format: Artigo
Jezik:Inglês
Izdano: Neoplasia Press 2021
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8322456/
https://ncbi.nlm.nih.gov/pubmed/34298234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2021.06.013
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki